Navigation Links
XTENT Announces Third Quarter 2007 Financial Results
Date:11/2/2007

MENLO PARK, Calif., Nov. 2 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the third quarter ended September 30, 2007.

The company reported a net loss of $9.5 million, or $0.42 per share, for the third quarter of 2007, compared to a net loss of $8.0 million, or $2.84 per share, for the same period last year. The company's net loss per share for the third quarter of 2007 was based on weighted average shares outstanding of 22.7 million as compared to 2.8 million weighted average shares outstanding for the quarter ended September 30, 2006. For the nine months ended September 30, 2007, XTENT had a net loss of $26.9 million, compared to $17.9 million for the same period last year. The net loss attributable to common stockholders was $26.9 million for the nine months ended September 30, 2007, compared to $31.0 million for the same period last year. At September 30, 2007, XTENT had cash, cash equivalents and short-term investments of $68.1 million.

Research and development expenses increased to $7.8 million in the third quarter of 2007 from $5.8 million for the same period last year primarily due to an increased number of research and development personnel and expenditures for prototype parts, supplies, and outside services related to product development for our Custom NX DES systems. General and administrative expenses were unchanged at $2.6 million in the third quarter of 2007 versus $2.6 million for the same period last year. Research and development expenses for the nine month period ended September 30, 2007, totaled $21.7 million, compared to $13.4 million for the same period last year. General and administrative expenses for the nine months ended September 30, 2007, totaled $7.9 million, compared to $5.3 million for the same period in 2006.

"We continue to make excellent progress in the development of our innovative stent systems," commented Gregory D. Casciaro, XTENT's President and CEO. "In October, we announced very encouraging results from our CUSTOM I and CUSTOM II clinical trials at the Transcatheter Cardiovascular Therapeutics (TCT) conference. At two year follow-up for CUSTOM I and one year follow-up for CUSTOM II, no new major adverse cardiac (MACE) events were reported. In addition, the incidence of late stent thrombosis in both trials was zero. Everyone at XTENT continues to be very focused on the execution of clinical, regulatory and product development milestones."

Third Quarter 2007 Highlights:

-- Completion of patient enrollment in the 90-patient CUSTOM III clinical

trial

-- Appointment of Michael Eagle, former Vice President, Manufacturing, at

Eli Lilly and Company, to the Board of Directors

-- Filed an Investigational Device Exemption (IDE) application with the

United States Food and Drug Administration (FDA) to begin the CUSTOM IV

pivotal trial. As the company announced on October 22, 2007, at the

Transcatheter Cardiovascular Therapeutics meeting in Washington D.C.,

it recently received questions back from the FDA regarding the IDE

application, and it is working to address these questions which must be

resolved before the company can initiate its Custom IV pivotal trial.

Conference Call and Webcast Information

The company will not be hosting a quarterly earnings call for the third quarter of 2007 as it provided an update during its conference call and webcast at TCT on October 22, 2007.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

XTENT, INC.

(a development stage company)

Condensed Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Operating expenses:

Research and development (1) $7,767 $5,844 $21,694 $13,403

General and administrative (1) 2,632 2,594 7,894 5,277

Total operating expenses 10,399 8,438 29,588 18,680

Loss from operations (10,399) (8,438) (29,588) (18,680)

Interest and other income, net 860 396 2,658 801

Net loss (9,539) (8,042) (26,930) (17,879)

Deemed dividend related to

beneficial conversion feature

of redeemable convertible preferred

stock - - - (13,095)

Net loss attributable to common

stockholders $(9,539) $(8,042) $(26,930) $(30,974)

Net loss per share attributable to

common stockholders - basic and

diluted $(0.42) $(2.84) $(1.35) $(11.65)

Weighted-average common shares

outstanding used in per share

calculation 22,656 2,830 19,999 2,658

(1) Includes the following stock-based

compensation charges:

Research and development $294 $524 $1,030 $850

General and administrative $490 $362 $1,322 $578

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

September 30, December 31,

2007 2006

Cash and cash equivalents and short term

investments $68,095 $23,105

Working capital 64,911 21,066

Total assets 72,338 27,121

Redeemable convertible preferred stock - 75,593

Deficit accumulated during the development

stage (80,996) (54,066)

Total stockholders' equity (deficit) 68,671 (50,780)


'/>"/>
SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Findings Could Reduce The Extent Of Spinal Cord Injuries
2. Students wants to extent Tution waiver in Ontario
3. Extent of Brain Involvement at Diagnosis May Predict Brain Atrophy
4. WTC Neighborhood Residents Misled on Extent of Contamination
5. PM announces a new health care order for India
6. Ramdoss Announces Introduction of RCH-II
7. Britain Announces Third Transfusion Related Mad Cow Case
8. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
9. Tibet Announces the Dalai Lama’s Tour of South Americ
10. NHS announces further Cost cutting Measures
11. Indian PM Announces Of Setting Up India Study Center At Tashkent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: